Cardiovascular Diseases

Juvenescence closes a USD 100 Million Series B round Juvenescence, a life sciences company focused on treating ageing problems, has successfully raised USD 100 Million in a Series B round. The investors who took part in the funding were Grok Ventures, the investment company of Mike Cannon-Brookes (Atlassian co-founder), and Michael Spencer’s private investment company, IPGL. Juvenescence, which utilizes artificial intelligence to develop therapies for age-related illnesses, such as cancer, diabetes, heart disease, respiratory disease, and dementia among others, till date has been able to net a total amount of USD 165 Million. According to WHO, around 50 million pe...